The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections (UTIs), the first such drug approved in decades and the first in a new class of medications.

coli) produce five to 16 times more protective capsular "slime" when Enterococcus faecalis ... coli (APEC)—cause urinary tract infections in dogs and bloodstream infections in poultry, respectively.

The U.S. Food and Drug Administration just approved the first new antibiotic to treat urinary tract infections in nearly three decades ... coli, Klebsiella pneumoniae, Citrobacter freundii complex, ...

In the current case series, daptomycin was shown to be a safe and effective therapeutic option in the management of VRE UTIs. Because of the increasing prevalence of VRE infection and the limited ...

In trials, the drug was effective against common UTI-causing bacteria ... Staphylococcus saprophyticus, and Enterococcus faecalis. "The approval of Blujepa is a crucial milestone, with uUTIs ...

Staphylococcus saprophyticus and Enterococcus faecalis. More than half of all women will contract this kind of UTI in their lifetime, and almost a third will battle recurring episodes. Blujepa ...

coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus and Enterococcus faecalis. More than half of women are affected by UTIs, common infections that affect the ...

The U.S. Food and Drug Administration just approved the first new antibiotic to treat urinary tract infections in nearly ... Citrobacter freundii complex, Enterococcus faecalis, and a type of ...

Background Vancomycin-resistant enterococci are a leading cause of hospital-acquired urinary tract infection and a growing concern for the clinician. The aim of this study was to evaluate the ...